6-amino-3-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1,6-dihydropyrimidin-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-amino-3-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1,6-dihydropyrimidin-2-one
• 化学式: C₉H₁₅N₃O₃
• 分子量: 213.23
• InChiKey: UZGQQJCQBSPTBY-YPVSKDHRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  87.8
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• ENHANCED OLIGONUCLEOTIDES FOR MODULATING FUBP1 EXPRESSION
  申请人：Hoffmann-La Roche Inc.

  公开号：US20220031730A1

  公开（公告）日：2022-02-03

  The present invention relates to enhanced antisense oligonucleotides that are complementary to the Far Upstream Element-Binding Protein 1 (FUBP1) and are capable of reducing a FUBP1 target nucleic acid, such as FUBP1 mRNA. The invention relates to enhanced antisense oligonucleotides targeting FUBP1 or conjugates thereof for use in treating and/or preventing a hepatitis B virus (HBV) infection, in particular a chronic HBV infection. The invention in particular relates to the use of the enhanced antisense oligonucleotides targeting FUBP1 or conjugates thereof for destabilizing cccDNA, such as HBV cccDNA. The invention further relates to enhanced antisense oligonucleotides targeting FUBP1 or conjugates thereof for use in treating cancer. A pharmaceutical composition and its use in the treatment and/or prevention of an HBV infection, or its use in the treatment of cancer is also disclosed.